Skip to content

Knowledge Hub

Learn how we're pioneering a new wave of precision medicine, explore our collection of publications, disease studies, webinars, thought leadership, and more

Newsletter signup

Blog

Our Philosophy

A deep dive into our unique approach and our mission to find better treatment options for patients with unmet medical needs

Publication

Cell Patterns: INDX systematic indication extension

Paper demonstrating the potential of indication extension to systematically reposition hundreds of drugs into new indications

Disease Study

COVID-19 disease study

Understanding the disease biology of COVID-19 to find novel drug targets and new treatment options

Disease Study

Alzheimer's disease study

Reducing the risk of future Alzheimer's disease clinical trial failures by identifying patient subgroups

Webinar

Disease mechanisms and novel target discovery

Watch on-demand as PrecisionLife CEO, Dr Steve Gardner, joins Cyclica CEO, Naheed Kurji, to explore disease mechanisms and novel target discovery

Blog

Proving the power of combinatorial analytics

A summary of how >70% of associated novel gene targets for severe COVID-19 identified with combinatorial analytics in May 2020 have now been independently validated

Publication

Complexity of disease biology gives opportunities for drug discovery

In this article, Dr Steve Gardner, CEO PrecisionLife, examines the lack of return on investment for pharmaceutical R&D and the huge pockets of unmet medical need in common chronic disorders

Disease Study

Diabetes type 2 complications disease study

Developing combinatorial risk scores to accurately predict and prevent type 2 diabetes complications

Blog

Why drug discovery & development needs fixing for chronic diseases?

The blockbuster model for drug discovery is inefficient and costly - a new approach that puts patients and their diverse disease biology at the center of R&D is needed

Sign Up

Subscribe to our blog